Peripheral Artery Disease (PAD)

01Pathophysiology

Peripheral artery disease is fundamentally atherosclerotic narrowing of the arteries supplying the lower extremities. The disease process is identical to coronary artery disease: endothelial injury, lipid deposition, inflammatory cell recruitment, and progressive plaque formation within the arterial intima. Because PAD, coronary artery disease, and cerebrovascular disease share the same systemic pathology, a patient diagnosed with PAD should be assumed to carry significant atherosclerotic burden elsewhere. This is a commonly tested concept: the presence of PAD is an independent predictor of myocardial infarction and stroke. The leading cause of death in PAD patients is not limb loss but cardiovascular events.

The most commonly affected site is the superficial femoral artery at the adductor canal (Hunter canal), where the artery is subject to repeated mechanical stress during leg movement. This anatomic detail explains why calf claudication is the most frequent symptom: the arterial obstruction sits proximal to the muscles it supplies, so the gastrocnemius and soleus become ischemic during exertion.

The pathophysiology directly maps to the clinical progression. At rest, even a moderately stenosed artery can deliver adequate perfusion because metabolic demand is low. During exercise, the working muscles require a several-fold increase in blood flow that the diseased vessel cannot provide. This supply-demand mismatch produces ischemic pain (claudication) that resolves within 2 to 5 minutes of rest once oxygen debt is repaid. As the disease worsens and stenosis becomes critical, blood flow fails to meet even resting metabolic needs, producing rest pain. Rest pain characteristically occurs at night when the patient is supine, because the loss of gravitational assistance further reduces perfusion pressure to the foot. Patients learn to dangle their legs over the bedside to restore gravity-dependent flow, and this history is a classic vignette clue. End-stage disease manifests as tissue necrosis: non-healing ulcers and gangrene, collectively termed critical limb ischemia.

Dependent rubor is another exam favorite rooted in pathophysiology. When perfusion pressure is critically low, arterioles maximally dilate as a compensatory response. In the dependent position, gravity fills these dilated, atonic vessels with deoxygenated blood, producing a dusky red discoloration of the foot. When the limb is elevated, the impaired arterial inflow cannot keep up, and the foot turns pale (elevation pallor). This combination of elevation pallor and dependent rubor is Buerger test, and it indicates severe disease.

02Classification and Clinical Manifestation

Two classification systems are tested. The Fontaine classification uses clinical stages, while the Rutherford classification uses categories and grades. Both describe the same disease continuum but Fontaine is more commonly referenced in clinical vignettes.

Fontaine Classification

Rutherford Classification

Arterial vs. Venous Ulcer Comparison

This distinction is tested repeatedly. The character of the ulcer often appears as the key discriminator in a vignette.

Acute Limb Ischemia (the "6 Ps")

Acute limb ischemia is a surgical emergency and warrants its own recognition framework. Exam vignettes present this as a sudden-onset cold, painful, pulseless limb, often in a patient with atrial fibrillation (embolic source) or known PAD (thrombosis in situ).

03Diagnostic Workup

The ABI is the cornerstone of PAD diagnosis and the answer to "what is the best initial test" in virtually every PAD vignette. Measurement involves placing blood pressure cuffs on both arms and both ankles, then using a continuous-wave Doppler to obtain systolic pressures. The ABI is calculated as:

$$ABI=\frac{\text{Highest systolic pressure at the ankle (dorsalis pedis or posterior tibial)}}{\text{Highest systolic pressure of either arm (brachial)}}ABI\; =\; \backslash frac\{\backslash text\{Highest\; systolic\; pressure\; at\; the\; ankle\; (dorsalis\; pedis\; or\; posterior\; tibial)\}\}\{\backslash text\{Highest\; systolic\; pressure\; of\; either\; arm\; (brachial)\}\}$$

A normal ABI ranges from 1.0 to 1.4. A value of ≤0.9 confirms the diagnosis of PAD with high sensitivity and high positive predictive value. Values between 0.4 and 0.9 correlate with claudication, while an ABI of <0.4 indicates critical limb ischemia with rest pain or tissue loss.

A critical pitfall on the exam involves patients with diabetes mellitus or advanced chronic kidney disease. These patients develop Monckeberg medial calcific sclerosis, which renders the tibial arteries non-compressible. The cuff cannot collapse the calcified vessel, so the measured ankle pressure is artificially high, yielding an ABI >1.4. This does not mean the patient is disease-free. In these cases, the next step is a Toe-Brachial Index (TBI), because the digital arteries of the toes are spared from medial calcification. A TBI of <0.7 confirms PAD.

If resting ABI is normal or borderline (0.91 to 0.99) but the patient's history is convincing for claudication, the next step is an exercise ABI. The patient walks on a standardized treadmill protocol, and the ABI is remeasured immediately after. A post-exercise drop of ≥20% in ankle systolic pressure, or a decline in ABI by ≥0.15, confirms hemodynamically significant PAD that is only unmasked during exertion.

Once PAD is confirmed, anatomic imaging is pursued only when revascularization is being considered. Duplex ultrasonography is the initial imaging modality because it is non-invasive, inexpensive, and readily available. For operative planning, CTA or MRA provides a roadmap of the vascular anatomy. Catheter-based digital subtraction angiography remains the gold standard for anatomic detail and doubles as a therapeutic tool, allowing balloon angioplasty and stenting during the same session.

04Management and Treatment

Cardiovascular Risk Reduction (All Patients)

Every patient with PAD receives aggressive cardiovascular risk modification, because (as noted above) the primary killer is not the leg disease but MI and stroke. This is the most commonly tested management principle for PAD.

Antiplatelet therapy with aspirin 81 mg daily or clopidogrel 75 mg daily reduces cardiovascular events. Dual antiplatelet therapy is not standard for stable PAD. However, the COMPASS trial showed that low-dose rivaroxaban (2.5 mg twice daily) combined with aspirin reduced both cardiovascular events and major adverse limb events in stable PAD, and this combination may appear in newer vignettes.

Statin therapy is indicated regardless of baseline LDL. High-intensity statin therapy (atorvastatin 40 to 80 mg daily or rosuvastatin 20 to 40 mg daily) is the standard.

Smoking cessation is the single most important modifiable intervention. It slows disease progression, improves claudication distance, and reduces cardiovascular mortality. Exam questions may frame this as "the most effective lifestyle modification."

Intermittent Claudication

Supervised exercise therapy is the first-line treatment for claudication. The protocol involves walking on a treadmill until near-maximal claudication pain is provoked, resting until the pain resolves, then repeating. Sessions last 30 to 45 minutes, 3 times per week, for at least 12 weeks. This approach promotes collateral vessel development and improves endothelial function. It is consistently shown to improve walking distance more effectively than pharmacotherapy alone. The key exam point: supervised exercise is superior to unsupervised "walk more at home" advice, which is a common distractor.

Cilostazol (100 mg twice daily, taken 30 minutes before or 2 hours after meals) is the pharmacologic agent of choice for claudication symptoms. It is a phosphodiesterase III inhibitor that causes vasodilation and inhibits platelet aggregation. The critical contraindication to memorize: cilostazol is absolutely contraindicated in patients with heart failure of any severity, because all phosphodiesterase III inhibitors increase mortality in heart failure (the milrinone class effect). If the vignette describes a claudicating patient with concurrent heart failure, the answer is NOT cilostazol. Pentoxifylline is a weak alternative with limited evidence; it is no longer strongly recommended but may appear as a less-preferred option.

Critical Limb Ischemia

Patients with rest pain, non-healing ulcers, or gangrene (Fontaine III or IV) require revascularization. Medical therapy alone is insufficient to prevent limb loss at this stage. The choice between endovascular (angioplasty with or without stenting) and open surgical bypass depends on anatomy: short-segment stenosis favors endovascular intervention, while long-segment occlusion or failed endovascular attempts favor surgical bypass with autologous saphenous vein graft. If both options have failed and infection or gangrene is progressing, amputation becomes necessary.

Acute Limb Ischemia

This is a time-sensitive emergency. The first step, even before imaging, is systemic anticoagulation with unfractionated heparin to prevent clot propagation. The patient then proceeds to emergent revascularization. If the limb remains viable and symptoms began within roughly 14 days, catheter-directed thrombolysis (tissue plasminogen activator infused directly at the clot) is preferred. If the limb is immediately threatened (paralysis, profound sensory loss), surgical thromboembolectomy via Fogarty balloon catheter is performed without delay.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most frequent way students lose points on PAD questions is by confusing the diagnostic approach when ABI is unreliable. A diabetic patient presents with classic claudication symptoms, and the ABI returns as 1.5. The untrained test-taker sees a "normal" or "high" ABI and concludes the patient does not have PAD. The correct interpretation is that the elevated ABI reflects non-compressible calcified vessels, and the next step is a Toe-Brachial Index, not reassurance.

A second common trap involves the management hierarchy. Students often jump to revascularization for claudication. The exam rewards understanding that supervised exercise therapy is the first-line treatment for intermittent claudication, not endovascular intervention. Revascularization is reserved for critical limb ischemia or claudication refractory to exercise and medical therapy that significantly limits the patient's livelihood.

The cilostazol-heart failure contraindication appears frequently in pharmacology-weighted questions. If the vignette mentions any degree of heart failure (reduced or preserved ejection fraction), cilostazol is the wrong answer regardless of how clearly the patient has claudication.

For acute limb ischemia, students sometimes delay anticoagulation while waiting for imaging. The tested principle is that heparin is given immediately upon clinical recognition of acute limb ischemia, before angiography. The rationale is to halt thrombus propagation while definitive revascularization is organized.

Finally, always remember the systemic nature of the disease. A question that seems to be about PAD may actually be testing whether you recognize that the most common cause of death in PAD patients is myocardial infarction, not limb amputation. The answer choices may include options focused solely on the limb, but the correct management always includes cardiovascular risk reduction (statin, antiplatelet, blood pressure control, smoking cessation) as the foundational layer.